Lexatumumab (also known as ETR2-ST01) is an experimental agonistic human monoclonal antibody against TRAIL-R2 (DR5 APO-2) undergoing clinical trials for the treatment of cancer.HGS-ETR2 antibodies were generated by HGS through a collaboration with Cambridge Antibody Technology.
This page contains content from the copyrighted Wikipedia article "Lexatumumab"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.